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Abstract 
5-HT4 receptor (5-HT4R) activation induces pro-cognitive effects. This might be related 
to stimulation of hippocampal acetylcholine (ACh) release, which has been shown for 
5-HT4R agonists in in vivo models. We investigated the influence of the 5-HT4R 
agonists prucalopride and BIMU-8 on ACh release in rat hippocampal brain slices. In 
contrast to the report by Siniscalchi et al. [1], no facilitating effect of 5-HT4R agonists 
on electrically evoked ACh could be shown. The in our hands absence of an effect by 5-
HT4R agonists illustrates that the in vitro evaluation of 5-HT4R agonists on 
hippocampal ACh release is not a straightforward model to study the relationship 
between hippocampal 5-HT4Rs and hippocampal ACh release. 
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Introduction 
Pharmacological studies have shown that 5-HT4 receptor (5-HT4R) activation induces 
pro-cognitive effects and increases memory and learning [2-5]. 5-HT4R have been 
shown to be present in the hippocampus [6,7]. The pro-cognitive effects of 5-HT4R 
stimulation might be the result of the induction of LTP (long-term potentiation) as 
shown in the amygdala [8] and suggested in the hippocampus [9], where 5-HT4R 
activation causes a long-lasting increase in excitability of CA1 pyramidal neurons 
[4,10,11]. On the other hand, the pro-cognitive effects of 5-HT4R agonists might also be 
related to the increased acetylcholine (ACh) release, as shown in vivo in the 
hippocampus [4] and the frontal cortex [12] of conscious freely moving rats. The loss of 
hippocampal cholinergic markers is indeed one of the major neurochemical deficits in 
Alzheimer’s disease (AD), which correlates well with the loss of cognitive abilities 
[13], and actual treatment of AD patients is mainly with cholinesterase inhibitors [14].  
In vitro, the facilitation of ACh release from guinea pig and rat hippocampal brain slices 
by 5-HT4R activation has been described by Siniscalchi et al. [1] and this paper is 
regularly cited to suggest the presence of presynaptic 5-HT4 heteroreceptors on 
hippocampal cholinergic nerve terminals [15,16] although no other reports on increased 
ACh release by 5-HT4R agonists in hippocampal brain slices have been published. In 
view of the report of Siniscalchi et al. [1], this study investigated the influence of the 
highly selective 5-HT4R agonist prucalopride on ACh release in rat hippocampal brain 
slices. 
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Materials and Methods 
In most experiments male Wistar rats (200-300g) were used. To rule out possible 
species differences due to variations in 5-HT4 receptor density, male Dunkin-Hartley 
guinea pigs (350-500g) were used in a series of experiments. Animals were housed 
under controlled conditions of temperature, humidity and light (12-h light/dark), and 
received food and water ad libitum. On the day of the experiment the animals were 
sacrificed by decapitation, under light CO2 anesthesia, and the brain was quickly 
removed to ice-cold modified Krebs’ solution of the following composition (mM): NaCl 
124.0 , KCl 3.0 , KH2PO4 1.25, MgSO4 1.0, CaCl2 2.0, NaHCO3 26.0, ascorbic acid 0.3, 
Na2EDTA 0.03, glucose 10.0 (pH 7.4) oxygenated with 95% O2 and 5% CO2. In 
experiments with guinea pig, the composition of the Krebs’ solution was as described 
by Siniscalchi [1]. The hippocampi were dissected from the cooled brain and coronal 
sections (rat: 350 µm; guinea pig 400 µm) were cut with a McIlwain tissue chopper to 
yield 16 dorsal hippocampal slices per animal. In a limited number of experiments, 
slices from rat were cut with a Microm HM 650V (Thermo Fisher Scientific, Waltham, 
MA) vibratome. To prepare the brain for cutting, the cerebellum and the frontal lobe 
were removed by a coronal section; the brain was then tilted on the frontal end to 
remove ventral-lateral areas (20°-30° off the horizontal axis). Finally, a medial sagittal 
cut was performed on the remaining tissue and the ventral lateral areas were glued onto 
the specimen holder of the vibratome. About eight horizontal 350 µm hippocampal 
slices were obtained per animal. Slices were loaded with [
3
H]-choline chloride (10 
µCi/ml, 0.1 µM) in 2 ml Krebs’ solution for 45 min at 37°C. The slices were rinsed 
three times and transferred to 200 µl chambers (4 per chamber) in an automated 
perfusion system (Brandel SF-2518B, Brandel Inc., Gaithersburg, MD). Perfusion was 
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done with carbogen-saturated Krebs’ solution containing 2µM hemicholinium-3 at a 
flow rate of 1.2 ml/min. After 1 hour of perfusion, 3 min samples of the effluent were 
collected and assayed for tritium content as a measure for [
3
H]-ACh. Electrical field 
stimulation (EFS) through platinum ring electrodes was applied twice at 15 and 45 min 
after the beginning of the collection period (S1, S2): biphasic square wave pulses were 
delivered by an ES-218 (Brandel) stimulator at 50 mA, 1 ms, at a frequency of 2 Hz for 
2 min (240 pulses). In guinea pig experiments, square wave pulses of alternating 
polarity were used. Drugs were added 15 min before S2. At the end of the experiments, 
tissues were homogenized by sonication in 0.5 ml of 10% trichloroacetic acid for 30 
min and a 100 µl aliquot was used to determine the amount of tritium remaining in the 
tissue. The tritium content of the sample was assayed by adding a 0.5 ml aliquot of 
perfusate samples to 2 ml Ultima Gold scintillation fluid (Perkin Elmer, Waltham, MA) 
and measured by liquid scintillation counting (Tri-Carb 2100 TR, Perkin Elmer) for 5 
min. Tritium outflow was expressed as fractional release, i.e. as a percentage of the total 
amount of tritium in the tissue at the time of sample collection. The uptake of tritium 
was determined as the sum of release plus tissue content of radioactivity at the end of 
the experiment. The release of tritium by EFS (stimulation-evoked release S1, S2) was 
calculated by subtracting basal release, measured for 9 min during the immediate pre-
stimulation period, from the release measured for 9 min from the start of the 
stimulation. The effect of the drugs on field stimulation-evoked tritium outflow was 
evaluated as the S2/S1 ratio compared to the S2/S1 ratio in control slices without drug 
addition. 
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Drugs: The following drugs were used: [
3
H]-methyl-choline chloride (Perkin Elmer; 
specific activity 75.7 Ci/mmol); hemicholinium-3 bromide and atropine sulfate (Sigma-
Aldrich, St-Louis, MO); 2-chloroadenosine (CADO; Fluka, Buchs, Switzerland); 
BIMU-8 (Tocris Cookson, Bristol, UK); prucalopride (Shire-Movetis, Turnhout, 
Belgium); tetrodotoxin (Serva, Heidelberg, Germany). All compounds were dissolved 
and diluted in distilled water. 
 
Statistics: For statistical analysis, GraphPad Prism version 5.0 (GraphPad, San Diego, 
CA) was used to perform one-way ANOVA followed by Bonferroni’s post-hoc test. 
The data were expressed as means ± s.e.m. p<0.05 was considered significant in all 
tests. 
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Results 
Fig. 1 illustrates the average tritium outflow from rat hippocampal slices obtained in 
control perfusion experiments. It can be seen that the basal release was stable and that 
the amount of electrically evoked tritium during the two episodes of electrical 
stimulation (S1 and S2) was similar yielding an average S2/S1 ratio of 1.09 ± 0.02 
(n=14). < position figure 1 > The electrically evoked tritium outflow was completely 
abolished by 3 µM tetrodotoxin (n=4; data not shown) indicating its dependence on 
action potential propagation through sodium channels. The assay was validated by 
perfusion of atropine (1 µM) or CADO (10 µM) 15 min prior to S2. As shown in Fig 2., 
atropine produced a consistent increase (+37%) of the evoked tritium outflow, with the 
average S2/S1 ratio being 1.48 ± 0.03 (n=8) while perfusion of CADO produced a 
consistent decrease (-55%) of the evoked tritium outflow, with the average S2/S1 ratio 
being 0.49 ± 0.04 (n=6) versus an average S2/S1 ratio of 1.08 ± 0.03 (n=10) in control.  
< position figure 2 >  However, neither BIMU-8 (2 µM), the 5-HT4R agonist that 
increased the tritium outflow in the study of Siniscalchi [1] by 43% nor the selective 5-
HT4R agonist prucalopride (1 µM) facilitated the ACh release from hippocampal brain 
slices (Figure 3). < position figure 3 >  None of the drugs modified the basal tritium 
outflow.  
Prucalopride did not affect the release of ACh at various perfusion times before S2 (24, 
18, 6, 3 min) or at different concentrations (0.01 µM, 0.1 µM) (n=1-2 for each 
condition). The data set presented above was obtained using a total K
+
 concentration of 
4.25 mM and a Ca
2+
 concentration of 2 mM in the Krebs solution; the effect of 
prucalopride has also been assessed in Krebs’ solution with high (5.9 mM) 
concentration of total K
+
 in combination with low (1.4 mM), intermediate (2 mM), or 
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high (2.5 mM) Ca
2+
 concentration (n = 1 for each condition). In addition, an experiment 
has been performed in the absence of EDTA and ascorbic acid. None of these 
conditions induced a facilitating effect of prucalopride on ACh release; neither did a 
different slicing method as similar S2/S1 ratios were obtained with vibratome-made 
slices (control S2/S1 ratio of 1.11 versus 1.12 with prucalopride; n=1). 
The absence of an effect by prucalopride was confirmed in hippocampal slices from 
guinea pig for two stimulation intensities: standard stimulation intensity as used for rat 
slices (2 Hz, 50 mA, 1 ms) yielded an S2/S1 ratio of 1.07 in control tissues versus 0.99 
in tissues treated with prucalopride (n=1); lower stimulation intensity (0.5 Hz, 50 mA, 1 
ms) led to an S2/S1 ratio of 0.93 in controls versus 0.92 with prucalopride present (n=1). 
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Discussion 
Our study confirmed that reproducible stimulation-induced release of ACh can be 
obtained from rat hippocampal slices [17-19]. In accordance with the literature the 
muscarinic receptor antagonist atropine increased and the mixed A1/A2a adenosine 
receptor agonist CADO decreased the evoked tritium outflow resulting from the 
blockade and stimulation of presynaptic inhibitory control on ACh release through 
muscarinic and A1 adenosine receptors, respectively [18,19]. In contrast with the report 
by Siniscalchi et al. [1], however, 5-HT4R activation did not modify the electrically-
evoked tritium outflow from rat or guinea pig hippocampal brain slices in the present 
study. To rule out the possibility that this discrepancy was a result of the slightly 
different experimental conditions used, the buffer composition, stimulus intensity, 
agonist and agonist perfusion time of the study by Siniscalchi [1] were additionally 
tested but no condition was obtained where 5-HT4R agonists showed a facilitating effect 
on ACh release from the hippocampal brain slices. 
Multiple variations in Krebs’ solution composition exist in the literature on rat 
hippocampal [
3
H]-ACh release [1,17-20]. Essentially total K
+
 concentration ranges from 
3 to 6 mM and/or Ca
2+
 concentration ranges from 1.2 to 2.5 mM. Adaptation of the K
+
 
and Ca
2+
 concentration of the Krebs solution did not induce a facilitating effect of 
prucalopride. The absence of an effect of the 5-HT4R agonists in the present study was 
thus not due to the buffer composition. 
Multiple variations in stimulation parameters exist in studies on rat hippocampal [
3
H]-
ACh release [1,17,19,20]. Square wave pulses (monophasic, biphasic or with alternating 
polarity) are used with typical pulse durations of 1 or 2 ms. Both voltage and current 
stimulation has been described with frequencies ranging from 0.5 Hz to 3 Hz and 
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stimulation durations from 2 to 4 min. As the intensity of nerve activation could indeed 
play an important role in the effectiveness of presynaptic receptors modulating 
transmitter release [21], the lowest stimulation intensity in terms of current and 
frequency yielding reproducible S2/S1 was used in the present study. The low 
stimulation intensity described by Siniscalchi et al. (30 mA/cm² at 0.5 Hz) reduced the 
ratio of evoked release to basal release in the experiments with rat tissue to such an 
extent that it impeded obtaining reproducible S2/S1; as in our experiments too, current 
stimulation was used, the delivered current should be identical in both setups. From the 
Siniscalchi data, however, the stability of the basal release and the ratio of evoked 
release to basal release cannot be appreciated as no graphical representation of the 
course of the release experiments was given. In experiments with guinea pig tissue, 
however, the ratio evoked release to basal release was higher than in experiments with 
rat tissue, which allowed stimulation at 0.5 Hz while preserving reproducible S2/S1. But 
still, this did not induce a facilitating effect of 5-HT4R agonists.  
In the study by Siniscalchi, the 5-HT4R agonist BIMU-8 was added to the perfusion 
medium 3 min before S2 to minimize the possibility of receptor desensitization [1]. As 
reducing the perfusion time or concentration of prucalopride before S2 did not increase 
the S2/S1 ratio obtained, receptor desensitization can be excluded as possible cause of 
the absence of an effect of the 5-HT4R agonists in the present study. 
We have no clearcut explanation for the discrepancy between our study and this of 
Siniscalchi et al.. It can still be mentioned that we used Wistar rats and Dunkin-Hartley 
guinea-pigs while Siniscalchi et al. used Sprague-Dawley rats and a not specified 
guinea pig strain. As the effects observed by Siniscalchi et al. were observed in both 
species, strain-dependency seems an unlikely explanation. More important, however, 
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could be the procedure used to obtain hippocampal slices. Moreover, it is still unknown 
whether 5-HT4 receptors that regulate ACh release within the hippocampus are located 
on cholinergic nerve terminals, cholinergic cell bodies or interneurons [16]. The 
absence of an effect of 5-HT4R agonists in our study could be the result of the 
disruption of essential cholinergic projections. The present data and the failure of 5-
HT4R agonists to enhance K
+
-evoked ACh release from hippocampal synaptosomes [1] 
suggest that 5-HT4 receptors are not located on the hippocampal cholinergic nerve 
terminals. A preterminal location of the 5-HT4R modulating ACh release could indeed 
make its functionality prone to the exact slicing procedure used. Unfortunately, 
Siniscalchi did not specify which specific part of the hippocampus was sliced and which 
slicing plane was used, which impeded exact mimicking of their slicing conditions. 
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Conclusion 
In rat and guinea pig hippocampal brain slices, no facilitating effect of the 5-HT4R 
agonists BIMU-8 and prucalopride on electrically evoked ACh release could be shown, 
in contrast to earlier data. The in vitro evaluation of 5-HT4R agonists on hippocampal 
ACh release is thus not a straightforward model to study the relationship between 
hippocampal 5-HT4Rs and hippocampal ACh release. 
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Figure 1 
Tritium outflow in control slices. Mean ± s.e.m. (n=14). 
Tritium outflow is expressed as a percentage of the tritium retained in the preparations 
at the time of the sample collection. The bars at S1 and S2 indicate the periods of EFS. 
In control experiments the evoked release of tritium remained constant during the 
consecutive stimulation periods, giving S2/S1 ratios close to unity. 
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Figure 2 
Effect of atropine (1 µM) and 2-chloroadenosine (CADO; 10 µM) on the stimulation 
evoked release of [
3
H]-ACh from rat hippocampal slices. Drugs were added to the 
perfusion solution from 15 min before the second stimulation period (S2) until one 
minute after S2 was ended. The ratio between the fractional release of [
3
H]-ACh in 
response to the first (S1) and second stimulation (S2) was calculated and compared in 
the absence and the presence of drug. Mean S2/S1 ratio ± s.e.m. (n=6-10). Asterisks 
show significant differences from control. *** P<0.001 (One way ANOVA; 
Bonferroni) 
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Figure 3 
Absence of an effect by prucalopride (1 µM) and BIMU-8 (2 µM) on the stimulation 
evoked release of [
3
H]-ACh from rat hippocampal slices. Drugs were added to the 
perfusion solution from 15 min before the second stimulation period (S2) until one 
minute after S2 was ended. The ratio between the fractional release of [
3
H]-ACh in 
response to the first (S1) and second stimulation (S2) was calculated and compared in 
the absence and the presence of drug. Mean S2/S1 ratio ± s.e.m. (n=6-8). 
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